Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to RMB2.5 billion of idle self-owned funds to purchase wealth management products, reflecting an effort to enhance returns on surplus liquidity without diverting capital from core operations. On 14 May 2026, the company entered four agreements with HTSC to invest a total of RMB453 million in low-to-medium risk, fixed-income wealth management products, a move that constitutes a discloseable transaction under Hong Kong listing rules and may modestly improve interest income while signaling prudent treasury management to investors.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The company focuses on developing and commercializing innovative therapies and operates in the healthcare and life sciences sector, deploying its financial resources to support research, operations, and strategic growth in its core drug development business.
Average Trading Volume: 4,162,412
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$69.16B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.